Aldehyde dehydrogenase isoform 1 (ALDH1) expression as a predictor of radiosensitivity in laryngeal cancer

Martín, Marta; Hinojar, A.; Cerezo, Laura; García, Jesús; López, Miguel Serrano; Prada, Justina; Marín, Alicia C; Gamallo, Carlos

doi:10.1007/s12094-015-1445-1

Cited by 9 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, our analysis did not show significant impact of ALDH1 expression on disease stage. The discrepancy of the results may be due to the recent publications [ 33 , 35 , 36 ] enrolled in the dataset which have shown no significant correlations between lymph node metastasis and CSC. Although a significant correlation of ALDH1 CSC with nodal status was not concluded in this meta-analysis, in patterns of primary tumor and its corresponding nodal metastases, we (Qian et al .)…”

Section: Discussionmentioning

confidence: 80%

“…DFS was investigated in 4 studies including 368 patients [ 17 , 31 – 33 ]. We performed a meta-analysis on the DFS of ALDH + and ALDH - patients.…”

Section: Resultsmentioning

confidence: 99%

“…We analyzed the OS of 672 patients from seven articles [ 5 , 17 , 29 , 30 , 33 , 36 , 37 ]. Using the DerSimonian–Laird fixed effects model, the meta-analysis on the OS of ALDH + and ALDH - patients did not reach a statistical significance (RR = 1.44; 95% CI: 0.93–2.23, P = 0.10, random effect; Fig 3B ).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Aldehyde dehydrogenase 1 isoenzyme expression as a marker of cancer stem cells correlates to histopathological features in head and neck cancer: A meta-analysis

et al. 2017

View full text Add to dashboard Cite

There is a lack of predictive biomarkers that can identify patients with head and neck squamous cell carcinoma (HNSCC) who will experience treatment failure and develop drug resistance, recurrence, and metastases. Cancer stem-like cells (CSC) were identified as a subset of cells within the tumor in a variety of solid tumors including HNSCC. CSC are considered the tumor-initiating population responsible for recurrence or metastasis and are associated with therapy resistance. This meta-analysis including fourteen studies with altogether 1258 patients updates and summarizes all relevant data on the impact of ALDH1+ CSC on the prognosis of HNSCC and its association with clinicopathological parameters. ALDH1 expression is highly correlated with tumor differentiation (G3 vs. G1+G2; odds ratio = 2.85. 95% CI: 1.72–4.73, P<0.0001) and decreased overall survival (relative risk = 1.77. 95% CI: 1.41–2.22, P<0.0001) if one out of seven studies was excluded because of heterogeneity. These findings provide insights into the understanding of more aggressive tumor phenotypes and also suggest that the prognostic value provided by HNSCC-subtyping by CSC frequency warrant further clinical investigation.

show abstract

Section: Discussionmentioning

confidence: 80%

“…DFS was investigated in 4 studies including 368 patients [ 17 , 31 – 33 ]. We performed a meta-analysis on the DFS of ALDH + and ALDH - patients.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Aldehyde dehydrogenase 1 isoenzyme expression as a marker of cancer stem cells correlates to histopathological features in head and neck cancer: A meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…It is ubiquitously distributed in various tumors, including BC, nonsmall-cell lung cancer, laryngeal cancer, ovarian cancer, and gastric cancer. [4–8] Many studies showed that ALDH1 is a marker of BCSCs, [3,5,9,10] while Kunju et al [11] reported that ALDH1-positive benign breast epithelial cells may predict an increased risk for the development of BC. Several studies suggested that ALDH1 is associated with an aggressive phenotype and poor prognosis, [12–16] although others found that it was not a survival predictor of BC [17–19] ; another study reported that expression of the major ALDH1 isoenzyme ALDH1A1 predicted a better outcome in BC of the triple-negative subtype.…”

Section: Introductionmentioning

confidence: 99%

Aldehyde dehydrogenase 1 expression is correlated with poor prognosis in breast cancer

Yao

Jin

Wang³

et al. 2017

Medicine

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most common cancers worldwide, and is a major cause of death in women. Aldehyde dehydrogenase 1 (ALDH1) is a marker of stem cells and cancer stem cells, and its activity correlates with the outcome of various tumors, including BC. This study aimed to analyze the relationship between ALDH1 expression and clinicopathological characters in BC and the prognostic significance of ALDH1.We used quantitative reverse-transcription PCR (qRT-PCR) to detect ALDHA1 mRNA levels in 25 fresh frozen BC samples and matched noncancerous samples. Immunohistochemistry on tissue microarrays was used to analyze protein expression in 137 paraffin-embedded BC tissues and corresponding noncancerous tissues. STATA 16.0 software was used for statistical analysis.The results suggested that levels of both ALDH1 mRNA and protein in BC were significantly higher than in corresponding adjacent breast samples (3.856 ± 0.3442 vs 1.385 ± 0.1534, P < .001; 52.6% vs 25.5%, P < .001, respectively). ALDH1 protein expression was also significantly associated with histological grade (P = .017), tumor size (P = .017), and tumor–node–metastasis (TNM) stage (P = .038). Multivariate analysis using the Cox regression model demonstrated that ALDH1 expression (P = .024), molecular typing (P = .046), and TNM classification (P = .034) were independent predictive factors for the outcome of BC. Kaplan–Meier analysis and the log-rank test indicated that patients with high ALDH1 expression, triple-negative BC, and advanced TNM stage had a reduced overall survival time.These data suggest that ALDH1 could be used as a prognostic factor for BC and may provide a useful therapeutic target in the treatment of BC.

show abstract

“…However, in a very recent study, the relapse rate in patients who underwent curative-intent radiotherapy or chemo-radiotherapy was lower in those with ALDH1 positive tumors [64]. These two studies providing conflicting data about the biomarker potential of ALDH1 for laryngeal CSCs necessitates further investigations to make certain of its potential as a CSCs biomarker.…”

Section: Other Potential Cancer Stem Cell Biomarkersmentioning

confidence: 97%

Current cancer stem cell biomarkers in laryngeal cancer

Karataş¹,

Barlak²,

Şahin³

2017

The European Research Journal

View full text Add to dashboard Cite

Larynx cancer (LCa), being an aggressive malignancy, is the second most commonly diagnosed malignant type of head and neck squamous cell carcinoma worldwide. Although there have been significant improvements in the detection and diagnosis of LCa in the last decades, it is still one of the considerable causes of cancer deaths and an urgent need for identification of novel biomarkers with diagnostic and prognostic significance still remains. The cancer stem cells (CSCs) resemble normal stem cells in terms of biological features and are considered to play critical roles in biological aggressiveness of tumors. Accumulating evidences have proven the existence of CSCs in various tumors including LCa and they are considered as driving force for tumor relapse, metastasis, and chemo-radioresistance. Comprehensive identification and characterization of the CSCs is of paramount importance for their further characterization to develop more effective and targeted therapeutic strategies against cancer. Here, we reviewed and summarized the most current literature to provide an insight into the functions and roles of current CSCs biomarkers in human LCa. We believe that this review will contribute to the knowledge of scientists especially working with LCa CSCs and will help understanding the significance of CSCs biomarkers implicated in LCa pathogenesis.

show abstract

Aldehyde dehydrogenase isoform 1 (ALDH1) expression as a predictor of radiosensitivity in laryngeal cancer

Abstract: The patients in this study with ALDH1 + tumours had better outcomes than their counterparts with ALDH1- tumours. This finding suggests that not all CSCs are resistant to conventional cancer treatments. It may also imply that new methods of correctly identifying these cells are needed.

Cited by 9 publications

References 24 publications

Aldehyde dehydrogenase 1 isoenzyme expression as a marker of cancer stem cells correlates to histopathological features in head and neck cancer: A meta-analysis

Aldehyde dehydrogenase 1 isoenzyme expression as a marker of cancer stem cells correlates to histopathological features in head and neck cancer: A meta-analysis

Aldehyde dehydrogenase 1 expression is correlated with poor prognosis in breast cancer

Current cancer stem cell biomarkers in laryngeal cancer

Contact Info

Product

Resources

About